• About Us
    • Contact Us
    • Login
    • ObGFirst
  • COVID-19
  • Alerts
  • OB
  • 2T US Atlas
  • The Genome
  • GYN
    • GYN
    • Sexual Health
  • Primary Care
  • Your Practice
  • GrandRounds
  • My Bookshelf
  • Now@ObG
  • Media
About Us Contact Us Login ObGFirst
  • COVID-19
  • Alerts
  • OB
  • 2T US Atlas
  • The Genome
  • GYN
    • GYN
    • Sexual Health
  • Primary Care
  • Your Practice
  • GrandRounds
  • My Bookshelf
  • Now@ObG
  • Media
The Genome
CMECNE

The Chromosome – Structure and Number

image_pdfFavoriteLoadingFavorite

Learning Objectives and CME/Disclosure Information

This activity is intended for healthcare providers delivering care to women and their families.

After completing this activity, the participant should be better able to:

1. Describe the architecture of a chromosome
2. Define aneuploidy and euploidy

Estimated time to complete activity: 0.25 hours

Faculty:

Susan J. Gross, MD, FRCSC, FACOG, FACMG
President and CEO, The ObG Project

Disclosure of Conflicts of Interest

Postgraduate Institute for Medicine (PIM) requires faculty, planners, and others in control of educational content to disclose all their financial relationships with ineligible companies. All identified conflicts of interest (COI) are thoroughly vetted and mitigated according to PIM policy. PIM is committed to providing its learners with high quality accredited continuing education activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.

The PIM planners and others have nothing to disclose. The OBG Project planners and others have nothing to disclose.

Faculty: Susan J. Gross, MD, receives consulting fees from Cradle Genomics, and has financial interest in The ObG Project, Inc.

Planners and Managers: The PIM planners and managers, Trace Hutchison, PharmD, Samantha Mattiucci, PharmD, CHCP, Judi Smelker-Mitchek, MBA, MSN, RN, and Jan Schultz, MSN, RN, CHCP have nothing to disclose.

Method of Participation and Request for Credit

Fees for participating and receiving CME credit for this activity are as posted on The ObG Project website. During the period from Dec 31 2017 through Dec 31 2019, participants must read the learning objectives and faculty disclosures and study the educational activity.

If you wish to receive acknowledgment for completing this activity, please complete the post-test and evaluation. Upon registering and successfully completing the post-test with a score of 100% and the activity evaluation, your certificate will be made available immediately.

For Pharmacists: Upon successfully completing the post-test with a score of 100% and the activity evaluation form, transcript information will be sent to the NABP CPE Monitor Service within 4 weeks.

Joint Accreditation Statement

In support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine and The ObG Project. Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician Continuing Medical Education

Postgraduate Institute for Medicine designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Continuing Nursing Education

The maximum number of hours awarded for this Continuing Nursing Education activity is 0.2 contact hours.

Read Disclaimer & Fine Print

WHAT IS IT?

A chromosome is the structure for the efficient packaging of DNA that is found in the cellular nucleus. Humans have 23 chromosome pairs, typically one maternal and one paternal of each.  The chromosome number will vary in some cases of viable aneuploidies.

Each chromosome has 2 “arms”

  • Short arm (petit), notated “p”
  • Long arm, notated “q”
  • Chromosomes are numbered, 1 through 23
    • 1 through 22 are autosomes, and is not related to whether one is female or male
  • Sex chromosomes are notated X and Y
    • Female Chromosome complement: 46,XX
    • Male Chromosome complement: 46,XY
This illustration depicts DNA packed tightly into chromosomes, as well as a DNA molecule unwound to reveal its 3-D structure.

This illustration depicts DNA packed tightly into chromosomes, as well as a DNA molecule unwound to reveal its 3-D structure | credit: NHGRI https://www.genome.gov

When the chromosomal complement is BALANCED (any multiple of 23), it is EUPLOID

  • ‘Balanced’ does not necessarily mean a normal chromosome complement | 69, XXY is euploid, but is considered to be a chromosomal abnormality

When the chromosomal number is NOT BALANCED, it is ANEUPLOID

  • Common chromosomal trisomies and monosomies are examples of aneuploidy
    • Trisomy 21 / Down syndrome (47, XX, +21 [female]; 47, XY, +21 [male])
    • Trisomy 13 and Trisomy 18
    • Klinefelter syndrome (47,XXY)
    • Turner syndrome (45,X)

Besides additional whole or missing chromosomes, chromosomes can have other structural changes, such as deletions (del), duplications (dup), insertions (ins), inversions (inv), many of which are associated with recognizable genetic syndromes, for example:

  • 22q11.2 deletion syndrome
  • Wolf-Hirschhorn syndrome (WHS): results from deletion of a portion of chromosome 4p

Not all structural changes have significance

  • inv(9)(p11q12) and inv(9)(p11q13): common inversions involving chromosome 9 with no clinical sequelae

KEY POINTS:

  • Chromosomal analysis requires only a single cell, at minimum, and can be performed on tissue/tumor, blood or amniotic fluid samples
  • Chromosomal analysis has an important role in prenatal diagnosis, clinical diagnosis in individuals with multiple congenital anomalies and other complex clinical pictures
  • Karyotype is a pictorial arrangement of chromosomes, that allows for careful analysis of gross numerical or structural changes
  • Chromosomal microarrays are being increasingly utilized as a method to analyze chromosomes as they offer the ability to detect submicroscopic abnormalities that may go undetected with conventional karyotyping (see ‘Related ObG Topics’ below)

Learn More – Primary Sources:

GHR: Chromosomes & mtDNA

CDC: Genetic Basics

NCBI: An Introduction to Genetic Analysis: Aneuploidy

NIH: NHGRI – Chromosomes

NIH: NHGRI – Chromosome Abnormalities

Take a post-test and get CME credits

TAKE THE POST TEST

Now You Can Get ObG Clinical Research Summaries Direct to Your Phone, with ObGFirst

ObGFirst® – Try It Free! »

image_pdfFavoriteLoadingFavorite

< Previous
All The Genome Posts
Next >

Related ObG Topics:

Down Syndrome / Trisomy 21: Clinical Findings and Prenatal Considerations
22q11.2 Deletion Syndrome – Key Clinical Highlights
Turner Syndrome – 45,X Explained
The Exome and Exome Sequencing: Prenatal Testing Recommendations
The Genome and Whole Genome Sequencing
Practical obstetrics info for your women's healthcare practice
Cystic Hygroma: Definition, Genetics and Prognosis
Intellectual Disability Defined
Klinefelter Syndrome: A Wide Range of Clinical Findings
Microarrays and Microdeletions: Key Concepts Summarized
Practical obstetrics info for your women's healthcare practice
Nuchal Translucency – First Trimester Measurement
Trisomy 13 – An Overview of Prenatal Findings and Outcomes
Trisomy 18 – Key Findings, Prenatal Screening and Prognosis

Sections

  • COVID-19
  • Alerts
  • OB
  • GYN
    • GYN
    • Sexual Health
  • 2T US Atlas
  • The Genome
  • Primary Care
  • Your Practice
  • Grand Rounds
  • My Bookshelf
  • Now@ObG
  • Media

Are you an
ObG Insider?

Get specially curated clinical summaries delivered to your inbox every week for free

  • Site Map/
  • © ObG Project/
  • Terms and Conditions/
  • Privacy/
  • Contact Us/
© ObG Project
SSL Certificate


  • Already an ObGFirst Member?
    Welcome back

    Log In

    Want to sign up?
    Get guideline notifications
    CME Included

    Sign Up

Get Guideline Alerts Direct to Your Phone
Try ObGFirst Free!

Sign In

Lost your password?

Sign Up for ObGFirst and Stay Ahead

  • - Professional guideline notifications
  • - Daily summary of a clinically relevant
    research paper
  • - Includes 1 hour of CME every month

ObGFirst Free Trial

Already a Member of ObGFirst®?

Please log in to ObGFirst to access the 2T US Atlas

Password Trouble?

Not an ObGFirst® Member Yet?

  • - Access 2T US Atlas
  • - Guideline notifications
  • - Daily research paper summaries
  • - And lots more!
ObGFirst Free Trial

Media - Internet

Computer System Requirements

OBG Project CME requires a modern web browser (Internet Explorer 10+, Mozilla Firefox, Apple Safari, Google Chrome, Microsoft Edge). Certain educational activities may require additional software to view multimedia, presentation, or printable versions of their content. These activities will be marked as such and will provide links to the required software. That software may be: Adobe Flash, Apple QuickTime, Adobe Acrobat, Microsoft PowerPoint, Windows Media Player, or Real Networks Real One Player.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information
presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Jointly provided by

NOT ENOUGH CME HOURS

It appears you don't have enough CME Hours to take this Post-Test. Feel free to buy additional CME hours or upgrade your current CME subscription plan

Subscribe

JOIN OBGFIRST AND GET CME/CE CREDITS

One of the benefits of an ObGFirst subscription is the ability to earn CME/CE credits from the ObG entries you read. Tap the button to learn more about ObGFirst

Learn More
Leaving ObG Website

You are now leaving the ObG website and on your way to PRIORITY at UCSF, an independent website. Therefore, we are not responsible for the content or availability of this site